SV2 PET Imaging With [11C]APP311

Recruiting Observational Study
Schizophrenia and Other Psychotic Disorders Cannabis Use Disorder Healthy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 85
Sex
Any
Study type
Observational
Participants needed
250 (estimated)
Sponsor
Yale University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Willing and able to give voluntary written informed consent * Male and Female subjects, age 18 to 65 years, inclusive Exclusion Criteria: * MRI metal exclusions and claustrophobia. * Education completed is less than 12 years
Contacts

Angerlyk Frytz, MD

203-974-7822

angerlyk.frytz@yale.edu

CONTACT